Keyphrases
Post-transplantation Cyclophosphamide (PTCy)
100%
Acute Myeloid Leukemia
81%
KLF4
75%
DNA Damage
75%
Myeloproliferative Neoplasms
75%
Mitosis
75%
Myelodysplastic Syndrome
75%
Relapse-free Survival
72%
Allogeneic Blood or Marrow Transplantation
56%
Mitotic Arrest
56%
Acute Lymphoblastic Leukemia
50%
Allogeneic Transplantation
50%
Hypomethylating Agents
50%
Chromosomal Instability
50%
Confidence Interval
50%
Myelodysplastic
50%
In Cancer
49%
SF3B1 mutation
47%
Plasma Tumor DNA
45%
Overall Survival
44%
Cancer Cells
41%
SF3B1
40%
Cell Proliferation
38%
Mitotic Checkpoint
38%
Human Cells
38%
Next-generation Sequencing
37%
Graft-versus-host Disease (GvHD)
37%
Myeloablative Conditioning
35%
SETBP1
35%
Cancer mutations
33%
PHGDH
33%
Tumor Growth
33%
Droplet Digital PCR (ddPCR)
32%
Estrogen Receptor 1 (ESR1)
32%
Isocitrate Dehydrogenase 1 (IDH1)
32%
Blood or Marrow Transplantation
31%
Graft-versus-host Disease Prophylaxis
31%
Nonmyeloablative
31%
ASXL1
31%
Low Risk
31%
Tumor
30%
Complete Remission
30%
SRSF2
30%
DNA Damage Response
30%
Centrosome Amplification
28%
Genome Stability
28%
Centrosome
28%
Endocrine Therapy
27%
Tumorigenesis
27%
Colorectal Cancer
26%
Biochemistry, Genetics and Molecular Biology
SF3B1
87%
Cancer Cell
77%
DNA Damage
75%
P53
70%
Serine
65%
Cell Proliferation
62%
Carcinogenesis
58%
Next Generation Sequencing
56%
Mitosis Inhibition
56%
Centrosome
54%
Reprogramming
50%
Chromosome Instability
50%
Droplet Digital Polymerase Chain Reaction
43%
KLF4
42%
Mediator
40%
Gene Targeting
37%
Oncogene
37%
Mouse
36%
Spindle Checkpoint
34%
Janus Kinase
33%
Fibroblast
32%
DNA Damage Response
32%
Promoter Region
30%
Homeostasis
29%
Splicing Factor
28%
Mitogen-Activated Protein Kinase
27%
Anchorage Independent Growth
27%
Wild Type
25%
Epidermal Growth Factor Receptor
25%
DNA Damage Checkpoint
25%
Cancer Incidence
25%
Estrogen Receptor
25%
N-Myc
25%
Missense Mutation
25%
Gene Expression
25%
ASXL1
25%
Estrogen Receptor Alpha
25%
Exon
25%
RUNX1
25%
Myeloid
25%
Gamma Secretase
25%
EZH2
25%
Factor V
25%
Overall Survival
25%
G Protein Coupled Receptor
25%
Cyclin B1
25%
Phosphoglycerate Dehydrogenase
25%
SOX4
25%
Bacteroides fragilis
25%
Single-Nucleotide Polymorphism
25%
Medicine and Dentistry
Acute Myeloid Leukemia
81%
Cyclophosphamide
75%
Myelodysplastic Syndrome
56%
Cancer Cell
56%
Overall Survival
55%
Disease
55%
Carcinogenesis
50%
Myeloproliferative Neoplasm
50%
Recurrence Free Survival
48%
Neoplasm
33%
Oncogene
33%
ASXL1
33%
Mitosis Inhibition
31%
Spindle Checkpoint
30%
Graft Versus Host Reaction
28%
Promoter Region
27%
Hazard Ratio
27%
Janus Kinase
26%
Neutrophilia
25%
Cell Line
25%
Cancer Treatment
25%
Gene Expression
25%
Chemokine Receptor
25%
Macrophage
25%
Hypomethylating Agent
25%
Factor V
25%
Tumour Heterogeneity
25%
Allotransplantation
25%
Prophylaxis
25%
Myelofibrosis
25%
Drug Megadose
25%
Ras Signaling
25%
Acute Lymphoblastic Leukemia
25%
Personalized Medicine
25%
Oncology
25%
Transplantation
25%
Cyclin B1
25%
Venetoclax
25%
Prostate Cancer
25%
Phagocytosis
25%
Nonmyeloablative Conditioning
25%
Exon
25%
Secondary Acute Myeloid Leukemia
25%
DNA Damage
25%
Malignant Neoplasm
21%
Spontaneous Remission
18%
Targeted Therapy
15%
Clinical Trial
15%
Cell Growth
15%
Cumulative Incidence
14%
